The Biopharmaceutical Analysis Training Laboratory
TRAINING TO CONDUCT COVID-19 TESTING
A critical mission in the U.S. and around the world is ramping up the number of tests for COVID-19 that can be processed quickly and accurately. The Biopharmaceutical Analysis Training Laboratory (BATL) is training employees at these sites virtually and respond to other needs of the healthcare and biopharmaceutical industries.
Led by Executive Director and Associate Teaching Professor Jared Auclair, BATL facilitates instruction on how to properly conduct RNA/DNA based testing and train personnel on GxP (Good Lab Practices, Good Clinical Practices, and Good Manufacturing Practices) that ensure sterility and compliance with clean room standards. The lab employs a Microsoft HoloLens to provide enhanced virtual training that allows us to teach up to 100 students in their home or at a training site.
BATL was created to improve patient access to safe healthcare products and health security and is an internationally recognized training partner for APEC and ICH in biologics, cell/gene therapies, and developing quality medications. It has served as a vital source for training in compliance with regulations of pharmaceutical, biopharmaceutical, and other related health products.
Endorsed and supported by the Massachusetts Life Sciences Collaborative, BATL is specifically designed to help increase skilled workforce development in the life sciences. The lab works closely with instrumentation companies, including Thermo, Agilent, and Waters; and biopharma, including Biogen, Roche-Genentech, Pfizer, and Amgen. Its faculty can provide training on proper administering of RNA/DNA-based or protein-based testing. BATL is also active in application-based research such as analytical, process, operational, and standards development, as well as diagnostic and therapeutic development.
How you can get involved
If you’re looking to support BATL, connect with Patty Flint, Assistant Vice President for Interdisciplinary Initiatives at email@example.com.